HMGB1, IL-1alpha, IL-33 and S100 proteins: dual-function alarmins

Damien Bertheloot

University of Bonn

*Et al.*
**REVIEW**

**HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins**

Damien Bertheloot¹ and Eicke Latz¹,²,³

Our immune system is based on the close collaboration of the innate and adaptive immune systems for the rapid detection of any threats to the host. Recognition of pathogen-derived molecules is entrusted to specific germline-encoded signaling receptors. The same receptors have now also emerged as efficient detectors of misplaced or altered self-molecules that signal tissue damage and cell death following, for example, disruption of the blood supply and subsequent hypoxia. Many types of endogenous molecules have been shown to provoke such sterile inflammatory states when released from dying cells. However, a group of proteins referred to as alarmins have both intracellular and extracellular functions which have been the subject of intense research. Indeed, alarmins can either exert beneficial cell housekeeping functions, leading to tissue repair, or provoke deleterious uncontrolled inflammation. This group of proteins includes the high-mobility group box 1 protein (HMGB1), interleukin (IL)-1α, IL-33 and the Ca²⁺-binding S100 proteins. These dual-function proteins share conserved regulatory mechanisms, such as secretory routes, post-translational modifications and enzymatic processing, that govern their extracellular functions in time and space. Release of alarmins from mesenchymal cells is a highly relevant mechanism by which immune cells can be alerted of tissue damage, and alarmins play a key role in the development of acute or chronic inflammatory diseases and in cancer development.

*Cellular & Molecular Immunology* (2017) ¹⁴, 43–64; doi:10.1038/cmi.2016.34; published online 29 August 2016

**Keywords:** alarmin; HMGB1; IL-1α; IL-33; inflammation; S100 proteins

**INTRODUCTION**

The immune recognition of an infection and the subsequent battle against the infecting pathogen is governed by the concerted efforts of both the innate and the adaptive immune systems. The first sensing of microbial invasion requires germline-encoded signaling receptors, also known as pattern-recognition receptors (PRRs), that evolved to acquire sensing specificity for foreign signature molecules generally termed pathogen-associated molecular patterns. This system was first theorized by Charles Janeway¹ 25 years ago, and has since been extended to include the more recently recognized ability of the innate immune system to also sense tissue damage by recognizing mislocalized or altered endogenous molecules termed damage-associated molecular patterns (DAMPs).²,³

These molecules found in a foreign environment trigger sterile inflammation and, in the best case, promote tissue repair and the resolution of the inflammation. However, innate immune responses can also fuel uncontrolled or chronic inflammation. Since the introduction of the DAMP model by Polly Matzinger,² many molecules that are released during proinflammatory cell death have been ascribed a DAMP function. These include heat-shock proteins (HSPs), adenosine triphosphate (ATP), nucleosomes, mitochondrial components and several alarmins: dual-function proteins that have distinct roles inside or outside the cells. The term alarmin describes protein functions leading to a rapid inflammatory response upon the release of these biologically active molecules. Notably, alarmins are also found in the nucleus in the resting state and likely exert biologically meaningful, yet understudied, functions. For example, failure of interleukin (IL)-33 to translocate to the nucleus results in a lethal inflammatory response, suggesting that the nuclear localization of, in this case, IL-33 has a protective function.⁴ In this review, we summarize recent knowledge on the most thoroughly studied dual-function proteins, the high-mobility group box 1 (HMGB1) protein, IL-1α, IL-33 and S100 proteins, with a focus on their extracellular functions.

¹Institute of Innate Immunity, University Hospitals, University of Bonn, 53127 Bonn, Germany; ²German Center for Neurodegenerative Diseases (DZNE), 53117 Bonn, Germany and ³Department of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01605, USA

Correspondence: Professor Dr Med E Latz, Institute of Innate Immunity, University Hospital, Sigmund-Freud-Strasse 25, 53127 Bonn, Germany.

E-mail: eicke.latz@uni-bonn.de

Received: 22 February 2016; Revised: 16 May 2016; Accepted: 17 May 2016
HIGH-MOBILITY GROUP BOX 1
HMGB1 is one of the most abundant nonhistone nuclear proteins and is a member of the HMG protein family that contributes to chromatin architecture and modulates gene expression. Once released from stromal or immune cells, and upon interaction with a large panel of cell surface receptors, HMGB1 exerts a plethora of cell regulatory functions, from maturation, proliferation and motility to inflammation, survival and cell death (Figure 1).

HMGB1 expression, cellular localization and post-translational modifications
In resting cells, HMGB1 is localized in the nucleus, where it exerts an important function for chromatin structure and gene expression (Figure 1).\textsuperscript{5,6} HMGB1 is involved in chromosomal DNA repair and contributes to nucleosome mobility by promoting histone sliding along the DNA strand. Consequently, Hmgb1 gene knockout is lethal, further arguing for the importance of HMGB1. Structurally, HMGB1 is composed of two DNA-binding HMG-box domains, namely Box A and Box B, followed by a flexible and negatively charged C-terminal tail. The C-terminal tail is believed to mediate a change in the three-dimensional structure of HMGB1 from a collapsed to a more linear conformation that most likely regulates HMGB1 binding to its ligands.\textsuperscript{7} Interestingly, post-translational modifications, such as acetylation, methylation and phosphorylation, have been shown to govern HMGB1 cellular localization (Figure 1).\textsuperscript{8–11} Upon activation, monocytes and macrophages were found to hyperacetylate HMGB1 at nuclear localization sites, leading to its cytosolic relocalization. This process was

Figure 1 Role of HMGB1 in inflammation. Under resting conditions, HMGB1 is localized in the nucleus, where it plays an important role in chromatin structure and gene expression. The translocation of HMGB1 to the cytoplasm is regulated by post-translational modifications such as acetylation, methylation and phosphorylation (1). Because of the lack of a secretion signal, HMGB1 is actively secreted through a caspase-1-dependent, noncanonical secretory vesicular pathway (2). HMGB1 can also be passively released from damaged cells either alone or in complex with RNA, DNA or nucleosomes (3). Interestingly, during apoptotic cell death, ROS production induces the terminal oxidation of HMGB1 that inhibits its proinflammatory function and switches HMGB1 function toward tolerogenicity (4). Once in the extracellular space, HMGB1 binds to several receptors in either free or complexed form (5). HMGB1 receptors, including RAGE and TLR4, bind free HMGB1 or HMGB1 in complex with DNA or LPS. Through its interaction with RAGE, the internalization of the HMGB1–DNA complex increases the activation of TLR9 localized in the endosome. However, HMGB1 complex formation with nucleic acids and potentially with other molecules can be inhibited by direct interaction with TIM-3. Other receptors, such as TLR2, IL-1R and CXCR4, recruit HMGB1 in complex with nucleosomes, IL-1β or CXCL12, respectively. Thus, sensing of HMGB1 mediates mechanisms of inflammation, cell migration, proliferation and differentiation (6). Furthermore, acting through the CXCL12/CXCR4 axis, HMGB1 enhances chemotaxis (7). HMGB1, high-mobility group box 1 protein; IL, interleukin; LPS, lipopolysaccharide; RAGE, receptor for advanced glycation end-products; ROS, reactive oxygen species; TLR, Toll-like receptor.
recently shown to be mediated by the activation of the JAK/STAT1 (Janus kinase/signal transducer and activator of transcription 1) pathway. In addition, in monocytes, HMGB1 cytoplasmic localization can be regulated by the phosphorylation of its nuclear localization signal, and this was found to depend on protein kinase C activity. Furthermore, in neutrophils, HMGB1 cytosolic translocation seems to depend on the methylation of Lys42 that decreases HMGB1 binding affinity to DNA and thus enables its translocation to the cytosol. These studies investigated the role of each modification in a rather exclusive manner. It is therefore difficult to conclude whether these mechanisms regulating HMGB1 cellular localization function in parallel or are differentially modulated in a cell type- or cell activation-dependent manner. Because the nuclear localization of HMGB1 is likely to act as a regulatory mechanism with regard to HMGB1 extracellular function, a more integrative study of HMGB1 post-translational modification will be necessary to better comprehend the regulation of HMGB1 cytosolic translocation before its release.

Adding to the complexity of HMGB1 activity, the redox state of HMGB1 is believed to orchestrate its extracellular function. HMGB1 possesses three cysteines at positions 23, 45 and 106. These enable three different oxidation states of HMGB1 that license three mutually exclusive functions: alarmin, chemoattraction or tolerance. In fact, the formation of a disulfide bond between Cys23 and Cys45 was shown to confer proinflammatory properties to HMGB1. Reduced HMGB1, with all cysteines in the thiol state, loses its alarmin function and behaves as a chemoattractant. In addition, upon cellular stress or apoptotic cell death, reactive oxygen species (ROS) production by mitochondria leads to the terminal oxidation of HMGB1 (sulfonate cysteines), granting HMGB1 tolerogenic properties that seem to mainly depend on Cys106 (Figure 1).

Consequently, post-translational modifications orchestrate HMGB1 activity from cell localization to extracellular function and thus act as a crucial functional switch.

**HMGB1 release and extracellular functions**

HMGB1 can be released either passively by necrotic and damaged cells or by active mechanisms triggered upon immune cell activation. Once released in the extracellular space, HMGB1 mediates inflammation, cell migration, proliferation and differentiation (Figure 1). In fact, extracellular HMGB1 was shown to act as a chemoattractant for myeloid cells, smooth muscle cells (SMCs) and mesoangioblasts, thereby promoting muscle tissue repair.

HMGB1 is considered to be one of the most mobile nuclear proteins and interacts only very transiently with chromosomal DNA. This loose nuclear DNA binding enables the leakage of HMGB1 upon cell damage or necrosis. In contrast, during apoptosis, HMGB1 was long believed to be trapped inside the nucleus, where it binds strongly to hypoacetylated chromatin. However, it was since demonstrated that oxidized HMGB1 can be released from late-stage apoptotic cells, thereby promoting tolerance in a caspase-1-dependent manner. It was also proposed that macrophages secrete HMGB1 following the phagocytosis of apoptotic cells, thus further challenging the idea that apoptosis is a ‘silent’ death.

In addition to the cell death-dependent release of HMGB1, which likely represents its most important role, immune cells such as macrophages and monocytes are known to actively secrete HMGB1 once stimulated by cytokines (interferon-γ (IFNγ), tumor necrosis factor (TNF) and IL-1) or pathogen-derived molecules (lipopolysaccharide (LPS)). Moreover, macrophages release HMGB1 following the activation of the NLRP3 or NLRC4 inflammasomes. Because HMGB1 lacks a leader sequence that would enable its transfer to the endoplasmic reticulum (ER) and the Golgi, active secretion of HMGB1 follows a nonclassical vesicular pathway. Indeed, several proteins, including not only HMGB1 but also IL-1β and IL-18, have been shown to depend on autophagy for their active secretion through the unconventional secretory pathway. Interestingly, following cell starvation, HMGB1 was proposed to enhance autophagy through its interaction with Beclin1, and this was dependent on ROS production and the HMGB1 redox state. HMGB1 cytoplasmic translocation both promoted autophagy and limited the apoptotic pathway. Thus, HMGB1 cytoplasmic translocation not only enables release but also can actively promote its own secretion.

Several receptors have been shown to trigger downstream signaling upon binding to HMGB1 either directly or in complex with other molecules (Figure 1). In macrophages and dendritic cells, HMGB1 binds directly to Toll-like receptor 4 (TLR4) and induces the secretion of proinflammatory cytokines. Interestingly, binding of HMGB1 to TLR4 depends on reduced Cys106. Moreover, the activation of TLR4 by proinflammatory HMGB1 (disulfide form) was recently shown to require myeloid differentiation factor 2 (MD-2). Upon binding to TLR4-MD-2, HMGB1 triggers the MyD88-dependent activation of nuclear factor (NF)-κB and the subsequent release of proinflammatory cytokines (i.e., TNFα, IL-1β and IL-6). Intriguingly, HMGB1 can also bind directly to LPS, thereby strengthening its ability to activate TLR4 through CD14. In contrast, binding of HMGB1 to CD24 and the further mobilization of Siglec-10 (or mouse Siglec-G) was shown to antagonize HMGB1-induced TLR4 activation in dendritic cells. In this study, Chen et al. found that the effect of CD24/Siglec-10 was restricted to stimulation with endogenous proteins (HMGB1, HSP70 and HSP90) and did not hold upon the activation of cells with pathogen-derived molecules. Hence, the authors proposed that the CD24/Siglec-10 pathway is a self-regulatory mechanism, limiting deleterious immune activation by endogenous damage-signaling molecules.

Another important cell surface receptor for HMGB1 is the receptor for advanced glycation end-products (RAGE). In fact, HMGB1 binding to RAGE was demonstrated shortly after RAGE discovery and has since been characterized in many settings. First, RAGE proved to mediate the previously described role of HMGB1 in neurite outgrowth during the...
development of the nervous system.\textsuperscript{40,41} In dendritic cells, HMGB1 release and sensing by RAGE was shown to be critical for homing to the lymph nodes and further cross-activation of T lymphocytes.\textsuperscript{42–44} In endothelial cells, HMGB1 was further shown to promote the expression of RAGE and surface adhesion proteins (intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1)) and also to induce RAGE-dependent cytokine production.\textsuperscript{45–47}

In addition to TLR4 and RAGE, HMGB1 interacts with several more receptors once in complex with other molecules. Indeed, extracellular HMGB1 can interact with IL-1β,\textsuperscript{48} CXCL12,\textsuperscript{49} and nucleosomes,\textsuperscript{50} thereby promoting the activation of IL-1 receptor (IL-1R), CXCR4 and TLR2, respectively. Furthermore, extracellular HMGB1, like other HMGB proteins, is found in complex with either DNA or RNA, promoting sensing by their putative receptors.\textsuperscript{51–53} Interestingly, yet another receptor of HMGB1, TIM-3, expressed at the surface of tumor-associated dendritic cells, was recently shown to compete with nucleic acids for binding to HMGB1, thereby dampening the efficacy of antitumor DNA vaccines or chemotherapy.\textsuperscript{54} These studies revealed the importance of controlling the purity of the recombinant HMGB1 protein used in experiments. In fact, several publications have argued that high-purity HMGB1 has a limited proinflammatory activity on its own.\textsuperscript{48,51,53,55} Yet, the propensity of HMGB1 to co-purify with innate immune stimulants is not the only characteristic that can influence its biological function. One has to take into account that different HMGB1 preparations can vary in their amount of protein oxidation, thus influencing the biological activity of recombinant HMGB1. In addition, although HMGB1 redox status has now been described as a major regulatory mechanism of HMGB1 extracellular function, the role of other known post-translational modifications of HMGB1 in the extracellular space remains unknown. Hence, in the future, it would be beneficial to further analyze the extracellular functions of HMGB1, paying special attention to its purity and to the exact nature of its post-translational state.

HMGB1 in sepsis and sterile injury

HMGB1 was shown to mediate several acute effects in the context of infection or sterile tissue damage following myocardial infarction, stroke, acute lung injury or ischemia–reperfusion injury often occurring after transplantation and trauma. During sepsis, HMGB1 acts as a late mediator of inflammation that can be sustained for several days and correlates with an unfavorable prognosis.\textsuperscript{29} In fact, upon infection, the presence of large amounts of pathogen-derived molecules, such as endotoxin, induces a biphasic secretion of cytokines:\textsuperscript{56} (1) the release of conventional proinflammatory cytokines, such as TNFα and IL-1β (peak levels are found within hours) and (2) the late release of HMGB1 that often leads to lethality. Interestingly, treatment of animals with anti-HMGB1 antibodies or the HMGB1-binding antagonist thrombomodulin provides protection even when administered several hours after the peak secretion of the early cytokines.\textsuperscript{45,57} In accordance with these findings, conditional deletion of HMGB1 in myeloid cells protected mice against LPS-induced endotoxic shock.\textsuperscript{58} Furthermore, a recent clinical study in which septic patients were treated with a combination of Polymyxin B and thrombomodulin found improved survival of the treated cohort.\textsuperscript{59} These data argue that HMGB1 may represent a pharmacological target for the treatment of septic shock. However, a study with larger groups and across different microbes and infection routes will be necessary before large-scale use in the clinic.

It is worth noting that the treatment of septic animals with recombinant HMGB1 A box, an antagonist competing with full-length HMGB1 for receptor binding, was also shown to provide protection against sepsis.\textsuperscript{50} In addition, the use of a monoclonal anti-RAGE antibody after cecal ligation and puncture (CLP) reduced lethality even when it was administered 36 h after CLP.\textsuperscript{61} This study followed the previous work by Lilienziek et al.,\textsuperscript{62} who first indicated a role for RAGE in the development of acute inflammation during sepsis. In addition to RAGE, the effects of HMGB1 in sepsis are believed to be partly mediated through TLR4.\textsuperscript{37,38} Further reinforcing this hypothesis, treatment of CLP-elicited septic mice with a specific inhibitor of HMGB1 binding to MD-2 (P5779) decreased lethality.\textsuperscript{37} However, as mentioned earlier, binding of HMGB1 to LPS strengthens TLR4 activation and thus could potentially contribute to HMGB1-induced acute inflammation following bacterial infection.

In contrast to its role during sepsis, in the context of sterile tissue damage and cell death, HMGB1 mediates early inflammation responses that only last hours. Indeed, HMGB1 levels increase in the circulation following major events such as stroke, myocardial infarction or hemorrhagic shock. These conditions induce an ischemia–reperfusion injury in tissues where HMGB1 is passively released.\textsuperscript{63–65} In these settings, both TLR4- and RAGE-dependent inflammatory pathways mediate the early effect of HMGB1 release. Indeed, in the ischemic liver and kidney, TLR4 was shown to trigger inflammation in response to HMGB1 release.\textsuperscript{54,65} Furthermore, RAGE expressed at the surface of microglial cells was found to mediate part of the deleterious function of extracellular HMGB1 in the ischemic brain.\textsuperscript{66} Strikingly, following brain injury, released HMGB1 was found to signal through RAGE in the lung, thereby mediating pulmonary dysfunction after lung transplantation.\textsuperscript{69,70} In accordance with this finding, HMGB1 release from gut epithelial cells was recently shown to mediate lung injury following trauma and hemorrhagic shock.\textsuperscript{71} These studies illustrate the ability of HMGB1 to mediate its alarm function in a systemic manner across the entire body. Here again, collaboration between RAGE and TLR4 is responsible for the deleterious effects of HMGB1 in acute sterile inflammation. Hence, direct targeting of HMGB1 with antibodies or thrombomodulin will probably be the most appropriate treatment strategy for transplanted patients or for those suffering from a traumatic injury. In fact, anti-HMGB1 antibodies have already shown some success in animal models of sterile inflammation and could therefore be promising for use in humans.\textsuperscript{68,72,73}
Role of HMGB1 in cancer

HMGB1 was studied for many years for its role in cancer and is now considered a central modulator of cancer development.47 In fact, HMGB1 expression increases in many types of cancer,75–77 correlates with tumor invasion and metastasis and relates to unfavorable prognosis.76,77,80,81 At the onset of tumorigenesis, rapid cell growth can overwhelm the limited blood circulation, thereby forming an ischemic environment that induces local cell necrosis and contributes to HMGB1 release.78 Moreover, during hypoxia, released HMGB1 activates the NLRP3 inflammasome and the subsequent caspase-1-dependent release of IL-1β and IL-18, fostering the inflammatory environment and promoting cell invasion.78 Ultraviolet irradiation of melanoma cells and the subsequent release of HMGB1 from damaged keratinocytes was also recently shown to induce a TLR4-dependent inflammatory environment that proved to be an important step toward perivascular invasion and metastasis in melanoma.82 Intriguingly, in pancreatic cancer cell lines, the presence of extracellular HMGB1 and its binding to RAGE seems necessary for mitochondrial ATP production and sustained cell growth.79 This study proposed that upon HMGB1 binding, RAGE translocates to the mitochondria, where it interacts with electron transport chain complexes I and II and thereby positively regulates oxidative phosphorylation. In addition, in the context of colorectal cancer, released HMGB1 can act on endothelial cells, promoting cell proliferation and neovascularization.81,85 Indeed, in vitro extracellular treatment with recombinant HMGB1 promotes endothelial cell migration and the NF-κB-dependent expression of adhesion and angiogenic proteins. Moreover, treatment with recombinant HMGB1 leads to TLR4 and RAGE expression. However, knockdown studies showed that HMGB1-dependent neovascularization is mainly mediated through RAGE.81 Further emphasizing the role of the RAGE–HMGB1 axis in cancer progression, blockade of either HMGB1 or RAGE can reduce malignant mesothelioma and glioma tumor growth and metastasis.80,84 Interestingly, upon anticancer treatment, the HMGB1 redox state balances the cell fate between autophagy-mediated cell survival or apoptosis.85,86 Indeed, using pancreatic and colon cancer cell lines (Panc2.03 and HCT116, respectively), Tang et al.85,86 demonstrated that treatment with cytokotic anticancer agents could induce both the autophagy and apoptosis pathways and subsequent HMGB1 release. In this study, the inhibition of autophagy decreased HMGB1 release and pushed the balance toward apoptosis. Reduced extracellular HMGB1 promoted autophagy and cell survival through a RAGE- and Beclin-1-dependent pathway. In contrast, oxidized HMGB1 promoted cell death and increased the efficiency of chemotherapeutic drugs. In accordance with these data, studies using different cancer cell lines (leukemia, colorectal carcinoma and pancreatic cancer cells) demonstrated a role for both RAGE and HMGB1 in the balance between autophagy and apoptosis through the modulation of p53-dependent apoptosis and the activation of ATG5-dependent autophagy pathways.87–89 In contrast, HMGB1 has been implicated in the antitumor immune response induced by radiation therapy or chemotherapy.90,91 In this case, HMGB1 enables the TLR4-dependent activation of dendritic cells and promotes antigen cross-presentation to cytotoxic T cells. However, these experiments did not consider the HMGB1 redox state. Hence, further analysis of the HMGB1 redox state in this setting would be of interest.

HMGB1 mediates chronic inflammation

There are many examples of the central role of HMGB1 in the development and aggravation of chronic inflammation. As a first example, extracellular HMGB1 has been associated with the development of arthritis, particularly with the inflammation of the synovial space. Indeed, HMGB1 levels are increased in the serum and synovial fluid of patients with rheumatoid arthritis (RA).92,93 The use of recombinant HMGB1 demonstrated that extracellular HMGB1 promotes the macrophage- and neutrophil-dependent development of arthritis.93,94 HMGB1 is actively secreted by synovial macrophages and fibroblasts in collagen-induced arthritis and hypoxic conditions.95 In this system, the effect of HMGB1 was shown to be partly mediated by TLR2 and TLR4.96 Consequently, the use of anti-HMGB1 monoclonal antibodies, thrombomodulin or A box peptide efficiently diminished inflammation and arthritis.95,97,98 Similarly, blocking HMGB1 release by nuclear sequestration using oxalatilin had protective effects.99 In accordance with these data, gold sodium thiomalate, a molecule often used to treat RA, was shown to block HMGB1 cytosolic translocation and thereby inhibit its secretion from macrophage cell lines.100

In addition, HMGB1 has been studied for its role in the development of systemic lupus erythematosus. Indeed, several studies have found the level of HMGB1 in the serum and skin lesions to be increased in patients with lupus, and this correlated with disease activity.101–105 Extracellular nucleosomes in complex with HMGB1 are believed to disrupt self-tolerance and promote the production of anti-double-stranded DNA antibodies.50,106 HMGB1 binding to DNA contained in immune complexes was also shown to enhance RAGE-dependent DNA intake and TLR9 activation, further increasing cytokine secretion and inflammation in lupus patients.51,53

Finally, in atherosclerotic plaques, SMCs are activated to secrete HMGB1. Interestingly, HMGB1 expression can be induced upon treatment with cholesterol, further linking HMGB1 to atherosclerosis.107,108 Upon sensing the Box B domain of HMGB1, SMCs proliferate and migrate. However, SMCs are not the only cell type secreting HMGB1 in atherosclerotic plaques. In fact, endothelial cells, macrophages, foam cells and activated platelets are also able to secrete HMGB1.109 As the NLRP3 inflammasome contributes to the formation of atherosclerotic plaques upon activation with cholesterol crystals,110 and its activation in macrophages leads to the active release of HMGB1,27,28 it is likely that the secretion of HMGB1 by plaque-infiltrating macrophages is NLRP3 dependent and contributes to the inflammation induced by cholesterol crystals present in the plaques. In this context, in vitro experiments showed that treatment with
extracellular HMGB1 increases the expression of adhesion molecules (ICAM-1 and VCAM-1) and promotes the secretion of proinflammatory cytokines (i.e., TNFα) and chemokines (i.e., CXCL8 and CCL2). In addition, RAGE expressed in endothelial cells is an important mediator of plaque formation. In fact, RAGE has long been known to promote the expression of adhesion proteins such as VCAM-1 in endothelial cells.111 During atherosclerosis, RAGE increases HMGB1 expression and release,112,113 and in vitro treatment of endothelial cells (human umbilical vein endothelial cells) with extracelluar HMGB1 induces RAGE-dependent ER stress.114 This implication of the RAGE–HMGB1 axis in the induction of ER stress could contribute to the previously mentioned induction of autophagy by HMGB1 through RAGE. Furthermore, during atherosclerosis, the HMGB1–RAGE axis has recently been implicated in platelet activation.116 Hence, in atherosclerotic plaques, HMGB1 sensing by platelets, endothelial cells and SMCs promotes the migration and adhesion of immune cells, thereby fostering plaque formation and growth.

For the past two decades, HMGB1 commanded the attention of many groups because of its central role in signaling infection and cellular damage. It has become clear that even if HMGB1 is an important mediator of necessary antimicrobial and tissue repair mechanisms, it also often acts as powerful deleterious ‘double-agent’ in the development of multifactorial diseases such as cancer and acute or chronic inflammation. Hence, the development of clinical tools targeting HMGB1 to moderate its negative effects will be crucial for the efficient treatment of many patients.

INTERLEUKIN-1α

The IL-1 family of proteins contains 11 members. The best-studied family members are IL-1α and IL-1β. Both are highly similar in structure and bind to the same cell membrane receptor, IL-1R. Interestingly, IL-1 receptor antagonist (IL-1Ra) is a naturally expressed member of the IL-1 family that is nonimmune stimulatory and inhibits both IL-1α and IL-β function by competing for binding to their receptor. Members of the IL-1 family are expressed as pro-forms (pIL-1) that are usually matured through enzymatic cleavage. Unlike IL-1β but similarly to all alarmins described herein, IL-1α is a dual-function cytokine that presents both nuclear and extracellular functions. Extracellular IL-1α is now recognized to be an important player in sterile inflammatory diseases and cancer.117–119

IL-1α expression and intracellular function

IL-1α precursor (pIL-1α) is constitutively expressed in most resting nonhematopoietic cells, such as epithelial cells lining the gastrointestinal tract, liver, kidney and skin.120,121 Moreover, pIL-1α expression can be increased in conditions of stress and inflammation.122 In resting cells, pIL-1α is found in the nucleus, where it promotes gene expression by acting as a transcription factor (Figure 2), regulating cell growth and differentiation. This relies on the N-terminal domain containing the nuclear localization signal,124 which is absent in mature IL-1α.124,125 Interestingly, following cleavage, the N-terminal domain of IL-1α was shown to independently translocate to the nucleus, where it interacts with certain members of the RNA splicing and processing machinery.126 In the nucleus, pIL-1α (but not mature IL-1α) also interacts with histone acetyltransferases and thus acts as a transcriptional regulator.123,127 In addition, upon stimulation with LPS or TNFα, pIL-1α translocates to the nucleus, where it was shown to promote the expression of inflammatory genes such as IL-6 and IL-8.125,126 In accordance with these findings, in systemic sclerosis fibroblasts, pIL-1α translocation was shown to depend on binding to HSP-associated protein X-1 (HAX-1) and induce the expression of IL-6 and pro-collagen (Figure 2). Interestingly, HAX-1 was also found to interact with the cleaved IL-1α N-terminal domain.130 Together, these studies suggest that the nuclear function of pIL-1α is predominantly dependent on its N-terminal domain. Upon cell activation, pIL-1α cleavage acts as a regulatory mechanism, keeping IL-1α outside the nucleus and Promoting its secretion. Furthermore, pIL-1α cleavage could support a distinct transcriptional function for the ‘freed’ nuclear N-terminal peptide. However, this hypothesis remains to be proven.

IL-1α secretion and extracellular activity

In stimulated cells, IL-1α is processed by the membrane-bound protease calpain, a calcium-dependent cysteine protease, and then released into the extracellular space.131–134 Similar to IL-1β and HMGB1, IL-1α does not contain any secretion signal and thus relies on the noncanonical vesicular secretion pathway (Figure 2). As for IL-1β, IL-1α secretion is believed to partially depend on caspase-1 activity. In fact, it was recently demonstrated that IL-1α secretion is antagonized by the intracellular presence of IL-1R2 which, through binding to pIL-1α, prevents its processing by calpain and further secretion. Active caspase-1 cleaves IL-1R2, thereby enabling pIL-1α processing by calpain and the release of mature IL-1α. However, Gross et al. showed that caspase-1 dependency for IL-1α secretion can differ depending on the stimulus and the targeted inflammasomes and does not seem to require the protease activity of caspase-1. IL-1α secretion may therefore rely on redundant parallel pathways. In fact, elevated intracellular Ca2+ triggers IL-1α secretion from bone marrow-derived cells. An increase in the Ca2+ concentration was shown to be sufficient for inflammasome-independent IL-1α processing by calpain and its subsequent secretion. Further differentiating itself from IL-1β and HMGB1, IL-1α activation and secretion is inhibited by autophagy. Indeed, in the context of Mycobacterium tuberculosis infection, ATG5-dependent autophagy was shown to block both the calpain-dependent activation of IL-1α and its secretion, thereby limiting lung inflammation and tissue damage.

Another regulatory mechanism seems to reside in the close proximity of IL-1α to the nucleus. Indeed, like HMGB1, cells undergoing apoptosis retain IL-1α in the chromatin fraction,
whereas necrotic cells can release pIL-1α, resulting in myeloid cell chemotaxis and inflammation. In fact, the IL-1α pro-form is known to bind to IL-1R1 and to induce inflammation. To date, however, it is not entirely clear which of the two forms is the most relevant following cell damage. Notably, IL-1α release by stressed endothelial cells was also proposed to be mediated by the formation of pIL-1α-containing apoptotic bodies that possessed chemotactic and proinflammatory properties.

In addition to calpain- and caspase-1-dependent pIL-1α processing, other proteases, such as granzyme B, elastase or chymase, have been proposed to cleave pIL-1α, producing the mature form of IL-1α and potentiating its proinflammatory activity. Interestingly, IL-1α may also be displayed at the cell surface, where it can activate juxtaposing target cells expressing its receptor, such as T cells or endothelial cells (Figure 2).

As for IL-1β, once it is released into the extracellular space, soluble or membrane-bound IL-1α binds to IL-1R1 and further triggers the recruitment of the accessory receptor IL-1R3 (also known as IL-1RAcP) for signal transduction. Downstream signaling is triggered by the recruitment of the MyD88 adaptor protein to the Toll–interleukin receptor domain of IL-1R3. As for other MyD88-dependent TLR signaling, MyD88 recruitment activates IRAK4/IRAK1 and subsequent downstream mitogen-activated protein kinase (MAPK) signaling and NFκB activation (Figure 2). Thus, IL-1α activates neighboring fibroblasts or epithelial cells, further triggering the release of chemokines that leads immune cells, preferentially neutrophils, to infiltrate and enhance local inflammation.

IL-1α in sterile inflammation: from acute to chronic disease

As previously mentioned, pIL-1α is constitutively expressed in most resting cells. It is therefore not surprising for pIL-1α to play a key role in inflammation induced by necrosis or tissue damage following ischemia. Indeed, liver lysates containing IL-1α promote neutrophil migration in matrigel. Moreover, in peritonitis, IL-1α is released from necrotic cells and subsequently activates IL-1R1 present at the surface of mesothelial cells. This was proposed to be the prime event inducing neutrophil infiltration and peritoneal inflammation rather than the HMGB1 pathway. This proinflammatory role of IL-1α was recently confirmed in a mouse model of acute colon inflammation (dextran sodium sulfate-induced colitis), where epithelial IL-1α played a key role in the establishment of inflammation. In contrast, IL-1β originating from myeloid cells promoted healing and tissue repair. One of the main triggers of cell necrosis is the hypoxia that follows poor oxygen supply associated with, for example, early-
stage tumor growth or blood vessel clogging. Interestingly, pIL-1α expression was shown to be increased before epithelial cell necrosis in a hypoxia-induced factor (HIF)-1α- and HIF-2α-dependent manner. The release of IL-1α promotes chemokine secretion and neutrophil infiltration. Moreover, extracellular pIL-1α itself can trigger the increased expression of pIL-1α (and pIL-1β) in surrounding cells, thereby fueling local inflammation. Following this early IL-1α-dependent inflammation and recruitment of neutrophils, inflammasomes and caspase-1 activation enable the cleavage of pIL-1β, promoting inflammation through the recruitment of macrophages. This mechanism is confirmed by the IL-1α dependency of IL-1β secretion following inflammasome activation.

During brain ischemia, activated platelets present in the brain vasculature were shown to release pIL-1α and thereby stimulate endothelial cells to secrete the chemokine CXCL1 and express the endothelial surface adhesion proteins VCAM-1 and ICAM-1. Hence, upon ischemic injury, pIL-1α fosters inflammation by enabling neutrophils to migrate through the endothelial barrier. Interestingly, platelets are known to be one of the first cell types to reach the brain and to be activated in response to stroke or in patients with multiple sclerosis. Thus, platelet-originating IL-1α would be an early signal playing a central role in the establishment of cerebrovascular inflammation and subsequently devastating brain injury.

Notably, similar mechanisms are involved in the ischemic heart following myocardial infarction. Indeed, IL-1α release from necrotic myocytes was shown to trigger acute inflammation by activating surrounding myofibroblasts.

The importance of IL-1α and IL-1β in sterile inflammation is further highlighted by the case of patients born with a deficiency in the IL-1R antagonist, IL-1Ra. Indeed, deficiency in IL-1Ra triggers IL-1-dependent inflammation and the infiltration of neutrophils to the skin, joints and bones. Systemic treatment with recombinant IL-1Ra (anakinra) has been an efficient way to decrease inflammation and prevent death. However, because anakinra can inhibit both IL-1α and IL-1β by binding to their common receptor, it is unclear which is the main cytokine at the root of the sterile inflammation affecting these patients. Nonetheless, anakinra is currently also used to treat RA as well as neonatal-onset multisystem inflammatory disease. Other drugs, such as monoclonal antibodies (canakinumab) and decoy receptors (rilonacept), are also used to treat patients presenting with, for example, juvenile idiopathic arthritis or cryopyrin-associated autoinflammatory syndrome, this time with a clear aim at blocking IL-1β-derived inflammation.

Yet, some evidence suggests a role for IL-1α in the development of these chronic inflammatory diseases. In fact, early IL-1α release is recognized as an important step that initiates inflammation, and IL-1α is thus considered a promising target for the treatment of rheumatologic disease. Interestingly, RA patients producing IL-1α-specific autoantibodies in the joint synovial fluid show reduced joint erosion. This supports the idea that IL-1α is a major player in the establishment of long-term inflammation. Furthermore, in a recent clinical trial, Coleman et al. used a monoclonal antibody (MABp1) targeting IL-1α for the treatment of psoriasis.

The role of IL-1α in cardiovascular diseases is not restricted to its proinflammatory function following myocardial infarction. Indeed, mounting evidence now suggests an important role for IL-1α in the development of atherosclerosis. This might come as a surprise because IL-1β has long been predicted to be the most important IL-1 cytokine responsible for vascular inflammation and the development of atherosclerotic plaques. Indeed, mice lacking either IL-1R or IL-1β or those treated with IL-1β-blocking antibodies presented decreased plaque formation. However, others have since shown that IL-1α deficiency in hematopoietic cells has an even more important protective effect. Together, these results therefore indicate a potential role for both IL-1α and IL-1β in atherosclerosis.

Perhaps, the greater effect of IL-1α in the development of aortic plaques might be in part attributed to the fact that IL-1α deficiency induces the decreased expression of IL-1β, thereby not only acting on IL-1α-dependent cell signaling but also acting in parallel on IL-1β function. Nevertheless, another study recently confirmed the results of Kamari et al. and further showed that IL-1α (but not IL-1β) secretion from LPS-stimulated macrophages is induced by unsaturated fatty acids (i.e., oleic acid) in an inflammasome-independent manner. In this study, unsaturated fatty acids were shown to act on the mitochondrial respiratory chain and induce its uncoupling, thereby promoting calcium fluxes and subsequent calpain-dependent IL-1α release. Moreover, by inducing mitochondrial uncoupling, oleic acid not only promoted IL-1α secretion but was also shown to inhibit IL-1β release. Hence, unsaturated fatty acids accumulating in atherosclerotic plaques would shift the IL-1 secretion by macrophages from IL-1β to IL-1α. Strikingly, analysis of IL-1α and IL-1β expression in either IL-1α/β-deficient macrophages indicated that not only IL-1α was upstream of IL-1β secretion but also that the reverse was potentially true. Indeed, IL-1β-deficient but not IL-1R-deficient macrophages showed markedly decreased IL-1α secretion and LPS-induced expression. This may indicate the existence of an IL-1β-dependent intracellular transcriptional control of IL-1α expression. However, this effect was only found in macrophages derived from the Il1btm1Yiw background. Macrophages derived from the Il1btm1Dch background had no effect on IL-1α secretion. These findings reveal the potential misconception regarding the role of IL-1β in atherosclerosis that might have been the result of underlying partial IL-1α downregulation. Caution will therefore be needed in the future when studying the role of IL-1β in atherosclerosis development.

IL-1α in cancer development

The existence of a link between chronic inflammation and the onset of tumorigenesis has long been postulated and is supported by many clinical conditions as well as cancer animal models. Yet, inflammation is also necessary for the
organism to fight against the tumor. In the middle of this tight equilibrium, the presence of proinflammatory signals, such as the previously mentioned HMGB1, can lead to tumor growth and invasion either way. Interestingly, IL-1R auto-
crine stimulation by IL-1α and downstream MyD88 activation were shown to be crucial for the establishment of the inflammation involved in RAS-dependent carcinogenesis. In these settings, IL-1α and MyD88 (but not IL-1β) activation trigger the loss of keratinocyte differentiation and promote invasiveness. Similar results have previously been found in melanoma patients, where IL-1α induced the MyD88-dependent activation of the NF-kB and MAPK pathways as well as an increase in ROS production, thereby promoting tumor progression. Furthermore, in pancreatic ductal ade-
nocarcinoma, tumor-associated IL-1α release, probably through cell damage, can also induce tumor growth via immune activation of the surrounding tumor fibroblasts. IL-1α is furthermore implicated in tumor vascularization by promoting the expression of vascular endothelial growth factor (VEGF) in endothelial cells. Interestingly, IL-1α seemed to have a more dramatic effect in hypoxic conditions, which fits to the proposed role of IL-1α in the often hypoxic tumor microenvironment. Following these first steps of tumor develop-
ment, IL-1β takes over and is thus believed to be of greater importance. Yet, clinical trials are underway using MABp1 antibody to target IL-1α in the treatment of refractory cancers with metastasis.

In contrast to the role of secreted IL-1α, intracellular and membrane-bound IL-1α activates immune mechanisms that lead to tumor destruction. Indeed, in a large panel of cancer cell lines, pIL-1α modulates cell cycle and induces apoptosis. In addition, overexpression of membrane-
bound IL-1α at the surface of fibrosarcoma or lymphoma cell lines induced loss of tumorigenicity. Once injected into mice, such cells form tumors that rapidly regress or cannot grow. Furthermore, after injection into wild-type (WT) mice, these cells induced the appearance of a long-
term memory against tumor cells that relied on the infiltration of CD8+ T cells, natural killer (NK) cells and macrophages.

Together, these data show that IL-1α could, in certain settings, represent a key initiator of proinflammatory mechan-
isms that drive chronic inflammatory diseases. Drugs in clinical use, such as anakinra, give hope for the targeting of IL-1α in these pathologies. However, the complex multifaceted func-
tions of IL-1α, sometimes beneficial and at other times deleterious, make IL-1α a difficult clinical target.

INTERLEUKIN-33

IL-33 is a member of the IL-1 family that is mainly expressed in the epithelium lining the surfaces in contact with the environment. IL-33 has long been considered to exclusively mediate type-2 immune responses. However, recent findings extended its influence to a broader panel of functions at the junction between innate and adaptive immune responses, from the maintenance of homeostasis to the mediation of deleterious proinflammatory reactions.

IL-33 protein expression and post-translational modification

Similar to IL-1α, IL-33 is an alarmin mostly expressed in stromal cells, such as endothelial cells, fibroblasts and the epithelial cells of tissues in contact with the environment. IL-33 (before known as NF-HEV) localizes to the nucleus thanks to a signal present at its N-terminal end (Figure 3). Because of its nuclear location and its release upon the loss of cell integrity, IL-33 was proposed to be another dual-function alarmin in line with HMGB1 and IL-1α. However, unlike HMGB1 and IL-1α, nuclear IL-33 represses gene expression by facilitating chromatin compaction. Furthermore, in addition to repres-
sing gene expression, IL-33 nuclear location was recently shown to act as a strong regulator of IL-33 extracellular function. Indeed, in chimeric mice expressing a N-terminally truncated IL-33, the exclusion of IL-33 from the nucleus induced lethal inflammation, suggesting that its nuclear location acts as a sink, preventing its uncontrolled extracellular release. This IL-33 nuclear ‘docking’ is even more important since its release is independent of prior processing either by caspase-1, caspase-8 (required for IL-1β or IL-18) or calpain (required for IL-1α). In fact, processing by caspase-1 or apoptotic caspases (caspase-3 and -7) occurs inside the IL-1-like domain, after asparagine 178, and was reported to inactivate the alarmin function of IL-33. Inactivation of IL-33 by caspases led at first to the consensus that full-length IL-33 is the active form (Figure 3). Yet, it was since proposed that IL-33 is cleaved to a mature and more proinflammatory form. In fact, in vitro studies demonstrated the cleavage of IL-33 by neutrophil elastase and cathepsin G. The resulting C-terminal cleavage products, containing the entire IL-1-like domain, after asparagine 178, and was reported to inactivate the alarmin function of IL-33. Inactivation of IL-33 by caspases led at first to the consensus that full-length IL-33 is the active form (Figure 3). Yet, it was since proposed that IL-33 is cleaved to a mature and more proinflammatory form.

Further amplifying the similarity of IL-33 with other alarmins, a recent study demonstrated that post-translational modification of IL-33 is an important regulator of IL-33 inflammatory function. However, unlike HMGB1, the oxidation of IL-33, occurring rapidly in the extracellular space, proved to be a crucial downregulator of IL-33 function (Figure 3). Such a mechanism would limit IL-33 in time and space, restricting its activity to the local environment. Interestingly, this study also showed that all IL-1 family members (except IL-1α and IL-36β) are subject to oxidation, thus revealing a potential common regulatory mechanism.
IL-33 downstream signaling

Similar to IL-1/IL-1R1 signaling, upon binding of IL-33, ST2 activation requires the accessory receptor IL-1R3 to function. Upon activation, ST2/IL-1R3 trigger signal transduction through a MyD88-IRAK-dependent pathway, leading to NF-κB, c-Jun N-terminal kinase (JNK) and MAPK activation. Thus, in mast cells, activation of NF-κB leads to the production of proinflammatory cytokines, such as IL-1β, IL-6 and TNFα. However, in mast cells or T cells, production of IL-5, IL-13 and the chemokines CCL5, CCL17 and CCL24 depends on the activation of MAPK signaling rather than NF-κB. Importantly, IL-33 activates naive T cells and promotes their maturation toward a Th2 phenotype, leading to the release of Th2-type cytokines and chemokines.

Interestingly, similar to RAGE, several ST2 splicing variants exist, producing either full-length, membrane-bound ST2 or a soluble protein thought to act as decoy receptor (sST2). For example, the use of recombinant soluble ST2 antagonizes the effect of IL-33 in allergic airway inflammation. In fact, soluble ST2 can bind to extracellular IL-33, thereby inhibiting its interaction with membrane-bound and signaling-competent ST2 (Figure 3).

IL-33 in infection and sepsis

Depending on the context, IL-33 was found to exert either deleterious or protective effects upon parasitic or viral infection by driving Th2-type responses. The role for IL-33 in parasitic infection was first suggested by the finding that upon infection of mice with Leishmania major, treatment with ST2-specific blocking antibodies ameliorated the disease, decreased parasite replication and switched the T cells toward a protective Th1 response. In a similar manner, following infection with respiratory syncytial virus, treatment with ST2-blocking antibodies reduced lung inflammation and the disease severity in mice primed for Th2-type but not Th1-type responses. In contrast, in the context of Trichuris muris infection, IL-33 expression was enhanced in resistant mice. After infection with T. muris, treatment with recombinant IL-33 conferred resistance against the infection and promoted a Th2 response (IL-4, IL-13 and IL-9) whereas it suppressed Th1- and Th17-type cytokine expression (IFNγ, TNFα and IL-6).

In the context of systemic inflammation, such as that occurring during sepsis, IL-33 was found to be beneficial. Indeed, in the murine CLP model, extracellular IL-33 inhibited the expression of G protein-coupled receptor kinase-2 (GRK2) and thereby blocked the TLR4-dependent downregulation of...
the chemokine receptor CXCR2 in neutrophils. This fostered neutrophil recruitment and microbial clearance at the local site of infection. Interestingly, although IL-33 did not affect the local release of proinflammatory cytokines, systemic IL-33 treatment reduced the concentration of blood and lung cytokines, thereby limiting the systemic inflammation induced by sepsis.

**IL-33 and chronic inflammatory diseases**

In the lung, epithelial cells are the main source of IL-33. Indeed, upon inflammatory stress, epithelial cells can be damaged and release IL-33 into the extracellular space. For example, IL-33 was shown to be deleterious during the development of asthma. In fact, the levels of IL-33 are higher in asthma patients than in normal individuals, and the same is true in a mouse model of ovalbumin (OVA)-elicited inflammation. Interestingly, when treated with blocking antibodies specific for ST2 or IL-33 at the time of OVA stimulation, mice presented diminished eosinophil infiltration, less inflammation and reduced airway hyperresponsiveness (AHR). The role for IL-33 in the development of exacerbated lung inflammation was recently further characterized in the context of chronic obstructive pulmonary disease (COPD) and viral infection-induced development of AHR. Cigarette smoke is considered one of the most important causes of COPD development. Moreover, in COPD patients, viral infection is often associated with acute exacerbation and AHR. Kearley et al. showed that cigarette smoke induces the increased expression of IL-33 in epithelial cells. Upon tissue damage induced by viral infection, this increased supply of IL-33 is released and exacerbates inflammation. Interestingly, the authors also demonstrated that cigarette smoke induced a shift in the type of immune response by controlling the expression of ST2 and IL-1R3. Indeed, cigarette smoke induced a dramatic decrease in ST2/IL-1R3 expression in Th2 T cells and type 2 innate lymphoid cells, thereby reducing the release of Th2-related cytokines (i.e., IL-5 and IL-13) by these cells. In parallel, cigarette smoke induced an increase in ST2/IL-1R3 expression in macrophages and NK cells that led to an increase in the secretion of TNFα, IL-12 and IFNγ. This could therefore explain the exacerbated inflammation found in COPD patients. Like HMGB1 and IL-1α, IL-33 was shown to be involved in other chronic inflammatory settings, such as atherosclerosis and arthritic joint inflammation. Indeed, recombinant IL-33 treatment of high-fat-diet ApoE−/− mice, an animal model of atherosclerosis, induced increased blood concentrations of IL-4, IL-5 and IL-13, whereas it decreased the level of IFNγ. Hence, in these settings, IL-33 switched the immune response from a Th1-type to a protective Th2-type response. In a similar manner, IL-33 and ST2 proved to have protective effects in the context of obesity. In fact, treatment of obese mice (ob/ob) with IL-33 increased the ST2-dependent levels of Th2 cytokines in the blood and adipose tissue and improved the metabolic parameters of these mice.

In opposition with its role in atherosclerosis, IL-33 was previously found to be deleterious in the context of arthritic joint inflammation. In fact, a dramatic increase in the synovial and serum levels of IL-33 was detected in patients with active RA. Moreover, when immunized with collagen, ST2-deficient mice developed strongly reduced arthritis when compared with WT mice. Treatment with recombinant IL-33 increased synovial inflammation and the secretion of proinflammatory cytokines by mast cells. As expected, treatment of collagen-immunized mice with ST2-specific blocking antibodies reduced the development of arthritic joint inflammation.

Together, the central position of IL-33 at the junction between the innate and adaptive immune responses makes it an important modulator of inflammation in a broad array of both acute and chronic inflammatory diseases. However, similarly to HMGB1 and IL-1α, IL-33 may prove to be a challenging drug target because of its variable effects in distinct inflammatory contexts.

**S100**

The S100 family of proteins is composed of 25 members that exert a large variety of intracellular and/or extracellular functions. Inside cells, S100 proteins regulate cell proliferation, differentiation, migration, energy metabolism, Ca2+ homeostasis, inflammation and cell death. Once released into the extracellular space, particular S100 proteins act as alarmins through their interaction with different receptors, orchestrating both innate and adaptive immune responses, cell migration and chemotaxis as well as tissue development and repair.

**S100 protein expression and intracellular functions**

S100 proteins are part of the calcium homeostasis machinery that has a crucial role in maintaining sufficient concentrations of intracellular Ca2+ for cell metabolism yet restricting excessive storage that could lead to Ca2+ precipitation or overwhelm the cell metabolism (Figure 4). The expression of the different S100 proteins is cell dependent and is regulated by specific growth factors, cytokines or activation of cell surface PRRs. Most S100 proteins are of rather small size (≤14 kDa) and are encoded by genes clustered on chromosome 1q21. One interesting exception to this rule is S100B, the coding gene of which is located on chromosome 21q22.3 and is found to be overexpressed in patients with Down syndrome. S100B is also unique in the fact that its expression has been associated with cells of neural crest origin, and it is now considered one of the best biomarkers of melanoma.

S100 proteins exert their intracellular functions in the nucleus or cytoplasm by interacting with other target molecules, such as enzymes, cytoskeletal proteins, receptors, transcription factors and nucleic acids. These interactions are often a critical step for Ca2+ binding and are therefore integral parts of calcium homeostasis. Another critical step for S100 protein activation is the formation of homo- or...
heterodimers. Binding of ions (Ca\textsuperscript{2+}, Zn\textsuperscript{2+} or Cu\textsuperscript{2+}) occurs via interactions with the S100 EF-hand domain, a conserved helix-loop-helix motif found in all calcium-binding proteins. Each S100 protein present in the dimer contributes to ion binding as well as to the interaction with the target molecules.\textsuperscript{233}

In healthy conditions, the functions of S100 proteins are extremely diverse and not only relate to the management of calcium storage and shuffling but also extend to specific cell functions such as transcriptional regulation and DNA repair (2), membrane protein recruitment and trafficking (3) and cytoskeleton assembly (4). The exact mechanisms that regulate the release of S100 proteins remain unclear thus far. Nevertheless, the secretion of S100 proteins occurs either passively upon cell damage or actively following cell activation (5). Once released into the extracellular space, S100 proteins interact with several receptors, most importantly RAGE and TLR4 (6). Upon binding to their receptors, S100 proteins trigger proinflammatory pathways promoting cell migration, proliferation and differentiation (7). S100 protein-induced signaling pathways also lead to the expression of MMPs and CAMs, thereby promoting chemotaxis and tissue remodeling (8). Certain S100 proteins, such as S100A8/A9, are extremely sensitive to oxidation (9). Their redox state acts as a molecular switch from proinflammatory function to protective wound-healing and antioxidant function. In return, oxidation-sensitive S100 proteins are believed to act as scavengers of ROS and NO and thereby prevent oxidative stress. CAM, cell adhesion molecule; MMP, matrix metalloproteinase; NO, nitric oxide; RAGE, receptor for advanced glycation end-products; ROS, reactive oxygen species; TLR4, Toll-like receptor 4.

S100 protein secretion, receptor interaction and post-translational modifications

S100 proteins have been detected in the extracellular space and certain body fluids, such as serum, urine, sputum, cerebrospinal fluid and feces, where they are generally associated with a state of disease.\textsuperscript{237–240} S100A8/A9, S100A12 and S100B are even considered biomarkers of specific diseases, such as cancer, atherosclerosis and stroke.\textsuperscript{231,241–245}

Like all alarmins previously described, S100 proteins lack a secretion leader sequence and therefore cannot be secreted through the classical ER–Golgi secretion pathway. The exact mechanisms that regulate the release of S100 proteins remain unclear thus far. Nevertheless, the secretion of S100 proteins occurs either passively upon cell necrosis or actively following cell activation (Figure 4). In fact, S100A8/A9 and S100A12 (also called calgranulins) were found to be released actively upon myeloid cell activation and subsequent tubulin-dependent translocation to the plasma membrane.\textsuperscript{245–248} S100A8/A9 were also found to be part of neutrophil extracellular traps, a mesh-like agglomerate composed of proteins and nucleic acids that are released as antimicrobial weapons by activated neutrophils.\textsuperscript{249} Similarly, S100B is released upon brain, lung or muscle tissue damage.\textsuperscript{250–253}
Once released to the extracellular space, S100 proteins trigger immune cell activation through binding to different cell surface receptors, thereby mediating different effects depending on the S100 protein and the target cell. Similar to HMGB1, RAGE is considered the most important cellular surface receptor for S100 proteins (Figure 4). S100A12 was the first S100 protein for which binding to RAGE was characterized, and this interaction is greatly increased by S100A12 capture of Ca²⁺ or Zn²⁺ ions. RAGE N-glycosylation also appears to play an important role for the recruitment of several S100 proteins and is believed to promote receptor clustering. Like S100A12, S100B binds to the RAGE V-domain and promotes RAGE multimerization and subsequent activation, thus promoting cell survival. In contrast, S100A6 is one of the rare RAGE ligands shown to interact with the RAGE C2-domain and was shown to have more of a proapoptotic effect. Interestingly, at the surface of myoblasts, S100B was shown to interact with the basic broblast growth factor receptor 1, leading to the recruitment and subsequent inactivation of RAGE. The S100A8/A9 heterodimer has also been proposed to bind to RAGE, triggering proinflammatory signaling and cell migration. Yet, the binding is rather weak and seems to rely on S100A9 and the presence of Ca²⁺ or Zn²⁺ ions. In fact, an extracellular function of S100A8/A9 has been associated with the activation of other receptors, and this has been the subject of controversy. Indeed, the S100A8/A9 heterocomplex was first believed not to bind to TLR4, and it was rather the S100A8 homodimer that was thought to bind to TLR4. More contradictory results came from another study that concluded that S100A9 bound better to TLR4-MD2 and that this was enhanced by the capture of Ca²⁺ and Zn²⁺. Recent data reinforced the potential role of S100A8 in the activation of TLR4 in monocytes. Treatment of mouse and human monocytes with S100A8 closely resembled LPS stimulation on the transcript level. TLR4 gene knockdown or steric inhibition studies demonstrated the proinflammatory effect of S100A8 stimulation to be TLR4 dependent. Furthermore, other receptors have been implicated in sensing S100 proteins, and these include G protein-coupled receptors, scavenger receptors and cell surface heparan sulfate proteoglycans.

It is important to note that similar to HMGB1 and IL-33, some S100 protein functions can be modulated by post-translational modifications, such as oxidation. For example, S100A8/A9 are very sensitive to oxidation, and their redox state acts as a molecular switch from a proinflammatory function (reduced) to a protective wound-healing and antioxidant function (oxidized). In contrast, oxidation of S100B was shown to be necessary for binding to RAGE and the subsequent increase in the expression of the angiogenic factor VEGF, an important player in the development of macular degeneration.

S100 proteins at the onset of acute inflammation

Upon release following cell death and tissue damage, several S100 proteins are passively released and act as DAMPs, signaling mainly through RAGE and TLR4, and thus contribute to the regulation of post-traumatic injury and inflammation following myocardial infarction, stroke or brain trauma.

For example, S100A1 is the most highly expressed S100 protein in cardiomyocytes and was shown to be released upon cell damage following ischemia–reperfusion injury associated with myocardial infarction. Once released, S100A1 activates the surrounding cardiac fibroblasts through TLR4 and triggers the MAPK and NF-κB proinflammatory pathways. However, S100A1 not only promotes proinflammatory signals but also regulates a complex balance between pro- and anti-inflammatory pathways associated with the anti-fibrotic upregulation of matrix metalloproteinase 9 (MMP9) and the downregulation of type I collagen and connective tissue growth factor. Moreover, S100A1-blocking antibodies increased fibrosis and infarction size, thus resulting in greater myocardial dysfunction. Hence, S100A1 plays a beneficial role following heart injury, promoting muscle tissue repair and maintaining contractility. Similarly, S100A4 release following myocardial infarction was shown to be protective by promoting SMC contractility. Similarly, S100A4 release following myocardial infarction, S100B can be released in high dose from injured cardiomyocytes and, through RAGE, further promote heart injury, promoting muscle tissue repair and maintaining contractility. Interestingly, at low doses, S100B promotes autophagy rather than apoptosis. S100B also promotes the RAGE- and NF-κB-dependent secretion of VEGF from cardiomyocytes, thereby engaging myofibroblast proliferation and scar formation.

Much attention has also been paid to the role of S100B in the central nervous system (CNS). In the brain environment, S100B function seems to be regulated by its concentration. Indeed, at low doses, S100B promotes neuron survival. However, in higher doses, S100B triggers apoptosis and is therefore associated with brain damage and neurodegeneration. In fact, S100B is released after stroke or following surgery and has been used as a marker to measure the extent of CNS damage and predict clinical outcome following brain injury.

S100 proteins and chronic inflammation

One example of the involvement of S100 proteins in the establishment of long-term chronic inflammatory disease is found in atherosclerosis. Indeed, while studying the influence of RAGE in the development of atherosclerosis in the
ApoE−/− mouse model, Harja et al.112 found the critical contribution of the S100B–RAGE axis in vascular inflammation and endothelial cell dysfunction during atherosclerotic plaque development. RAGE expression by endothelial cells was found to increase the expression of adhesion molecules (VCAM-1), cytokines and chemokines as well as MMP2 in the aortic tissue, thereby promoting the recruitment of immune cells to the forming plaque. The in vitro stimulation of primary endothelial cells with S100B was shown to replicate these findings and to trigger the activation of the extracellular signal-regulated protein kinase-1/2 (ERK1/2) and JNK proinflammatory pathway. In addition to S100B, serum S100A12 levels are increased in patients with coronary artery disease after plaque rupture.281 Thus, S100A12 is now being considered a biomarker of coronary artery disease.244 In this circumstance, S100A12 inhibits MMP2, 3 and 9 in atherosclerotic plaques.281 Moreover, the presence of S100A12 promotes remodeling and calcification of atherosclerotic plaques in a RAGE-dependent manner in transgenic ApoE−/− mice expressing human S100A12 in SMCs.282,283 Plaque calcification is believed to be partly mediated by SMCs that, under oxidative conditions, undergo an S100A12/RAGE-dependent procalciﬁcation phenotypic switch to osteoblast-like cells.284,285 Similarly, S100A8/A9 are found in abundance in macrophages and foam cells present in human atherosclerotic plaques, where they were shown to promote dystrophic calcification.285,286 However, the oxidation-sensitive nature of S100A8/A9 present in high amounts in atherosclerotic plaques might mean that the complex acts as an oxidant scavenger and thus promotes wound healing and protects other cell components against damaging oxidation.271

In correlation with their role in atherosclerosis development, S100A8/A9 were shown to drive the RAGE-dependent and hyperglycemia-induced increase of myelopoiesis occurring in diabetic mice.287 Indeed, in diabetic mice (streptozotocin-elicted or from an Ins2Akita background), the release of S100A8/A9 by activated neutrophils induced the RAGE-dependent proliferation of granulocyte and macrophage progenitor cells in the bone marrow. This increased the total quantity of monocytes and neutrophils infiltrating atherosclerotic lesions and thus impaired plaque regression. Interestingly, antidiabetic treatment normalizing the glycemia of Ldlr−/− atherosclerotic mice was sufficient to decrease the number of circulating monocytes and neutrophils and thereby reduced the atherosclerotic lesions. Most importantly, an increase in the serum white blood cell count correlated with a higher S100A8/A9 concentration in patients with coronary artery disease.287 In accordance with these data, increased serum levels of S100A8/A9 were found in obese patients and were linked to the increased expression of the macrophage marker CD68 in the visceral adipose tissue.288,289 However, S100A8/A9 serum levels were found to be reduced to normal levels following weight loss. These results, together with the previously mentioned studies linking S100A8/A9 to atherosclerosis development, may partly explain the prevalence of atherosclerosis associated with obesity and diabetes. In addition, blood levels of S100A12 have been found to be increased in diabetic patients and to correlate with a higher risk of cardiovascular disease development.244

Further implicating S100 proteins in the development of chronic inflammatory diseases, calgranulins (S100A8/A9 and S100A12) were shown to be involved in the joint inflammation associated with RA.290 S100A8/A9 are highly upregulated in macrophages and neutrophils from patients with juvenile rheumatoid arthritis, and S100A8/A9 titers in the serum and synovial fluid correlates with disease severity.247,291 The S100A8/A9 and S100A12 synovial ﬂuid protein levels were found to speciﬁcally correlate with RA and were proposed as speciﬁc markers to differentiate RA from other forms of inflammatory arthritis.292,293 In this context, S100A8/A9 were found to originate from monocytes, which release S100A8/A9 upon interaction with activated endothelial cells, thereby enhancing the inflammatory environment.247 Extracellular stimulation of human monocytes with S100A8/A9 was later shown to trigger NF-κB activation with subsequent release of proinflammatory cytokines.294 In addition to their monocytic origin, S100A8/A9 expression was found to be increased in chondrocytes present in the inﬂamed joints of IL-1Ra-deﬁcient mice that rapidly develop arthritis-like symptoms. In this context, stimulation of chondrocytes with extracellular S100A8 activated the NF-κB pathway and the subsequent release of cytokines and several MMPs,295 and this stimulatory activity was subsequently attributed to signaling through TLR4.296 It is also interesting to note that RAGE expression increases in the joints of arthritic mice.297 Indeed, an Ager gene polymorphism coding for the G82S mutation was shown to increase the binding of S100A12 in vitro and promoted S100A12-induced inﬂammation.297 This is even more interesting because this Ager G82S polymorphism has a higher prevalence in RA patients.297 Local intra-articular corticosteroid treatment of RA patients induced reduced concentrations of serum and synovial S100A12, further linking calgranulins to the arthritic joint inﬂammatory environment.298 Together, these studies demonstrate the central role of S100A8/A9 and S100A12 in the establishment of the inﬂammatory microenvironment present in the arthritic joints and the metalloproteinase-dependent destruction of cartilage. It is also worth noting that the synovial ﬂuid level of calgranulins found in active arthritic joints is higher than the serum levels, further supporting the idea of an intra-articular origin of calgranulins (infiltrating macrophages and granulocytes or chondrocytes).247,294,298 However, the exact role of TLR4 or RAGE in this context is not yet entirely clear.

In addition to calgranulins, both S100A4 and S100B were found to activate the ERK1/2 and NF-κB proinflammatory pathways through RAGE expressed at the surface of chondrocytes, thereby triggering an increase in MMP13 expression that could potentially contribute to arthritic cartilage destruction.299,300 Notably, several S100 proteins have been linked to the development of skin lesions in psoriasis. Indeed, S100A8/A9 levels were shown to be elevated in psoriatic skin lesions.301,302 Stimulation of normal keratinocytes with S100A8/A9 induced
the secretion of proinflammatory cytokines and chemokines that in turn promoted S100A8/A9 expression in an autocrine-positive feedback loop, thus mimicking the proinflammatory environment found in psoriatic lesions. Furthermore, S100A7 and S100A15 were shown to promote the chemotraction of monocytes, neutrophils and CD4+ T cells and trigger the production of proinflammatory cytokines in the context of psoriatic skin lesions. However, only S100A7 required RAGE for its chemotactic activity, underlining potential differences in the role of S100A7 and S100A15 in psoriasis.

**S100 proteins and cancer**

Like all of the alarmins described above, several S100 proteins have been identified as central mediators for the development of a multitude of cancers and have been shown to contribute to tumor cell proliferation, metastasis, angiogenesis and immune evasion. The role of S100 proteins in cancer is considered as central mediators for the development of a multitude of cancers and have been shown to contribute to tumor cell proliferation, metastasis, angiogenesis and immune evasion. Several groups recently reviewed the intricate role of S100 proteins in cancer in great detail.

**CONCLUDING REMARKS**

A large body of evidence suggests that several proteins hidden inside cells have both intracellular roles and extracellular functions that contribute to the rapid recruitment and response of the immune system to infection and damage. During chronic damage and metabolic perturbations, these proteins are integral to complex proinflammatory events with shared regulatory mechanisms that result in either tissue repair or tissue damage and organ dysfunction. The pharmacological targeting of such DAMPs could therefore be of benefit. However, alarmins have intricate local and systemic roles which depend on their post-translational modification status, differential receptor engagement and the cell-type affected. Thus, targeting alarmins remains challenging.

**ACKNOWLEDGEMENTS**

We acknowledge research support provided by the NIH (RO1-HL112661), the Deutsche Forschungsgemeinschaft (SFB670, 645, 704, 1123, TRR57, 83, Exc1023) and the European Research Council (ERC InflamMAct).

---


Spears LD, Razani B, Semenkovich CF. Interleukins and atherosclerosis: a dysfunctional family grows.


194 Caryol C, Girard J-P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. *Proc Natl Acad Sci USA* 2009; **106**: 9021–9026.


196 Lefrançais E, Roga S, Gauthier V, Gonzalez-de-Peredo A, Monsarrat B, Girard J-P et al. IL-33 is processed into mature bioactive forms by neutrophil elastase and cathepsin G. *Proc Natl Acad Sci USA* 2012; **109**: 1673–1678.

197 Schmitz J, Ouyang A, Oldham E, Song Y, Murphy E, McLellan TK et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. *Immunity* 2005; **23**: 479–490.

198 Chackerian AA, Oldham ER, Murphy EE, Schmitz J, Pachman LM. IL-1 receptor accessory protein and ST2 comprise the T1/ST2-IL-33 pathway. *J Immunol* 2009; **182**: 1777–1787.


244 Oesterle A, Hofmann Bowman MA. S100A12 and the S100/ RAGE, carboxylated glycans and S100A8/A9 play essential roles in multimeric S100B. EMBO J 2007; 26: 3868–3878.


251 Foell D, Frosch M, Sorg C, Roth J. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997; 272: 24956–24960.


300 Yammani RR, Carlson CS, Bresnich AP, Loefer RF. Increase in production of matrix metalloproteinase 13 by human articular chondrocytes due to stimulation with S100A4: Role of the receptor for advanced glycation end products. *Arthritis Rheum* 2006; **54**: 2901–2911.


309 Leclerc E, Vetter SW. The role of S100 proteins and their receptor RAGE in pancreatic cancer. *Biochim Biophys Acta* 2015; **1852**: 2706–2711.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/